BGI Genomics Co., Ltd
Research BGI Genomics Co., Ltd (300676.SZ) on Bullrun: market cap CNY 16.49B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker300676.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyCNY
- Market capCNY 16.49B
- Financial periodQ2 2026
- RevenueCNY 979.86M
- Net incomeCNY 56.93M
- Free cash flow-CNY 159.31M
- Gross margin43.0%
Valuation Snapshot
latest market cap is CNY 16.49B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 16.49B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CNY.
About BGI Genomics Co., Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BGI Genomics Co., Ltd's market cap?
BGI Genomics Co., Ltd's market capitalization is CNY 16.49B.
What does BGI Genomics Co., Ltd do?
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing.